Arcellx (ACLX) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual meeting scheduled for May 28, 2025, to be held virtually, with voting on key proposals including director elections, executive compensation, and auditor ratification.
Board recommends voting for all proposals, including the election of three Class III directors, approval of executive compensation, and ratification of PricewaterhouseCoopers LLP as auditor.
Stockholder engagement was emphasized, with outreach to top shareholders and incorporation of feedback into disclosures and governance practices.
Forward-looking statements highlight ongoing risk factors and future plans, with a focus on continued growth and operational execution.
Voting matters and shareholder proposals
Proposals include electing three Class III directors, an advisory vote on executive compensation (Say-on-Pay), and ratification of PricewaterhouseCoopers LLP as independent auditor for 2025.
Board recommends voting for all proposals; voting is available online, by phone, mail, or during the virtual meeting.
Shareholders of record as of April 4, 2025, are eligible to vote; quorum requires a majority of outstanding shares.
Procedures for submitting shareholder proposals and director nominations for the 2026 meeting are detailed, with specific deadlines and requirements.
Board of directors and corporate governance
Board consists of eight directors, seven of whom are independent; board is divided into three classes with staggered three-year terms.
Two new directors appointed in March 2025; board diversity and experience are emphasized.
Board committees include audit, compensation, and corporate governance/nominating, each with defined responsibilities and independent membership.
Board leadership combines CEO and Chairman roles, with best practices such as executive sessions and regular assessments.
Board and workforce diversity metrics are highlighted, with 50% women and 75% diverse representation on the board.
Latest events from Arcellx
- Net loss increased to $228.9M in 2025; Gilead acquisition and FDA BLA review underway.ACLX
Q4 202526 Feb 2026 - 97% response rate, deep MRD negativity, and no delayed neurotoxicity in RRMM.ACLX
Status Update11 Jan 2026 - Anito-cel demonstrates best-in-class efficacy and safety, targeting a 2026 launch with strong growth prospects.ACLX
TD Cowen 45th Annual Healthcare Conference23 Dec 2025 - Anito-cel delivers 96% response, 74% CR, and no delayed neurotoxicity in advanced myeloma.ACLX
Status Update19 Dec 2025 - Virtual meeting to elect directors, approve pay, and ratify auditor, with board support.ACLX
Proxy Filing2 Dec 2025 - Anito-cel demonstrates robust efficacy, unique safety, and readiness for a 2026 launch.ACLX
TD Cowen's 6th Annual Oncology Innovation Summit24 Nov 2025 - Anito-cel combines best-in-class efficacy, safety, and operational scalability for broad myeloma adoption.ACLX
Status Update14 Nov 2025 - Net loss rose to $170.8 million as collaboration revenue fell and G&A expenses increased.ACLX
Q3 20255 Nov 2025 - Anito-cel shows robust efficacy and safety, targeting a 2026 launch with broad market potential.ACLX
Morgan Stanley 23rd Annual Global Healthcare Conference21 Oct 2025